F
Francesco Giuseppe Foschi
Researcher at Academy for Urban School Leadership
Publications - 124
Citations - 3944
Francesco Giuseppe Foschi is an academic researcher from Academy for Urban School Leadership. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 27, co-authored 103 publications receiving 2942 citations.
Papers
More filters
Journal ArticleDOI
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
Fabio Conti,Federica Buonfiglioli,A. Scuteri,Cristina Crespi,Luigi Bolondi,Paolo Caraceni,Francesco Giuseppe Foschi,Marco Lenzi,Giuseppe Mazzella,Gabriella Verucchi,Pietro Andreone,Stefano Brillanti +11 more
TL;DR: In patients with HCV-related cirrhosis, DAA-induced resolution of HCV infection does not seem to reduce occurrence of HCC, and patients previously treated for HCC have still a high risk of tumour recurrence in the short term, despite DAA treatment.
Journal ArticleDOI
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
Paolo Caraceni,Oliviero Riggio,Paolo Angeli,Carlo Alessandria,Sergio Neri,Francesco Giuseppe Foschi,F. Levantesi,Aldo Airoldi,S. Boccia,Gianluca Svegliati-Baroni,Stefano Fagiuoli,Roberto Giulio Romanelli,Raffaele Cozzolongo,Vito Di Marco,Vincenzo Sangiovanni,Filomena Morisco,Pierluigi Toniutto,Annalisa Tortora,Rosanna De Marco,Mario Angelico,Irene Cacciola,Gianfranco Elia,Alessandro Federico,Sara Massironi,Riccardo Guarisco,Alessandra Galioto,Giorgio Ballardini,Maria Rendina,Silvia Nardelli,Salvatore Piano,Chiara Elia,Loredana Prestianni,Federica Mirici Cappa,Lucia Cesarini,L. Simone,Chiara Pasquale,M. Cavallin,Alida Andrealli,F. Fidone,Matteo Ruggeri,A. Roncadori,Maurizio Baldassarre,Manuel Tufoni,Giacomo Zaccherini,Mauro Bernardi,Marco Domenicali,Ferdinando Giannone,Manuela Merli,Stefania Gioia,Silvano Fasolato,Antonietta Sticca,Daniela Campion,A. Risso,Giorgio Maria Saracco,D. Maiorca,Agostino Rizzotto,Arianna Lanzi,Elga Neri,Anna Visani,Antonio Mastroianni,A Alberti,Chiara Mazzarelli,Marcello Vangeli,Marco Marzioni,Francesca Capretti,Alba Kostandini,G. Magini,M. Colpani,Giacomo Laffi,T Gabbani,Maria Marsico,M. Zappimbulso,Josè Petruzzi,Vincenza Calvaruso,Giovanni Parrella,Nicola Caporaso,Francesco Auriemma,Maria Guarino,Fabio Pugliese,Antonio Gasbarrini,Pietro Leo,Francesco De Leonardis,A. Pecchioli,Piera Rossi,Giovanni Raimondo,Elisa Negri,Marcello Dallio,Carmelina Loguercio,Dario Conte,Natascia Celli,R. Bringiotti,N.M. Castellaneta,Francesco Salerno +92 more
TL;DR: Long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis in this trial.
Journal ArticleDOI
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study
Alessandro Vitale,Patrizia Burra,Anna Chiara Frigo,Franco Trevisani,Fabio Farinati,Gaya Spolverato,Michael L. Volk,Edoardo G. Giannini,Francesca Ciccarese,Fabio Piscaglia,Gian Lodovico Rapaccini,Mariella Di Marco,Eugenio Caturelli,Marco Zoli,Franco Borzio,Giuseppe Cabibbo,Martina Felder,Antonio Gasbarrini,Rodolfo Sacco,Francesco Giuseppe Foschi,Gabriele Missale,Filomena Morisco,Gianluca Svegliati Baroni,Roberto Virdone,Umberto Cillo +24 more
TL;DR: Resection could result in survival benefit over LRT for HCC patients regardless of their BCLC stage, provided that liver dysfunction (Child B or MELD>9) and PST>1 are absent.
Journal ArticleDOI
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Giorgia Marisi,Alessandro Cucchetti,Paola Ulivi,Matteo Canale,Giuseppe Cabibbo,Leonardo Solaini,Francesco Giuseppe Foschi,Serena De Matteis,Giorgio Ercolani,Martina Valgiusti,Giovanni Luca Frassineti,Mario Scartozzi,Andrea Casadei Gardini +12 more
TL;DR: The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.
Journal ArticleDOI
Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC.
Francesca Fornari,Manuela Ferracin,Davide Treré,Maddalena Milazzo,Sara Marinelli,M. Galassi,L. Venerandi,Daniela Pollutri,Clarissa Patrizi,Alberto Borghi,Francesco Giuseppe Foschi,Giuseppe Francesco Stefanini,Massimo Negrini,Luigi Bolondi,Laura Gramantieri +14 more
TL;DR: It is shown that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of micro RNAs into the extracellular compartment.